MODIFICATION
Q -- High Performance Liquid Chromatography / Tandem Mass Spectroscopy (LC-MS/MS)for Therapeutic Drug Monitoring - Amendment P0001
- Notice Date
- 9/13/2013
- Notice Type
- Modification/Amendment
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-13-T-0369
- Response Due
- 9/18/2013
- Archive Date
- 11/12/2013
- Point of Contact
- Terry Bice, 210-539-3295
- E-Mail Address
-
US Army Medical Research Acquisition Activity
(terry.g.bice.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- SUMMARY OF CHANGES - Solicitation W81XWH-13-T-0369 SECTION SF 1449 - CONTINUATION SHEET SOLICITATION/CONTRACT FORM The required response date/time has changed from 13-Sep-2013 05:00 PM to 18-Sep-2013 05:00 PM. The following have been modified: PERFORMANCE WORK STATEMENT Performance Work Statement High Performance Liquid Chromatography / Tandem Mass Spectroscopy (LC-MS/MS) for Therapeutic Drug Monitoring 1. Background: The U.S. Army Institute of Surgical Research (USAISR) is a subordinate command of the U.S. Army Medical Research and Materiel Command (USAMRMC). The USAISR is dedicated to both laboratory and clinical research in order to optimize combat casualty care. 2. Requirements: The vendor shall (for each batch of samples submitted): a. Receive the samples from USAISR via FedEx shipping in cooler boxes shipped with dry ice once a week. b. Perform analysis on submitted serum samples using High Performance Liquid Chromatography / Tandem Mass Spectroscopy (LC-MS/MS) for either Fentanyl and Norfentanyl or Buprenorphine and Norbuprenorphine. Samples will be identified to determine which analysis to perform. It is imperative that High Performance Liquid Chromatography is run in tandem with the Mass Spectroscopy to achieve the quality and reliability required. c. Required sensitivity: Fentanyl 0.1 ng/mL Norfentanyl 0.2 ng/mL Buprenorphine 0.5 ng/mL Norbuprenorphine 0.5 ng/mL d. Each assay must not require more than 2.0 mL of serum or plasma per sample. e. All test procedures must be subjected to matrix and /or QA validation f. Perform either the Fentanyl and Norfentanyl serum analysis or the Buprenorphine and Norbuprenorphine analysis in batches as submitted. Analysis will be performed at identical settings to allow for comparison across groups and studies. g. Complete either the Fentanyl and Norfentanyl or the Buprenorphine and Norbuprenorphine analysis of each sample in each submitted batch and deliver a report of the batch results to the Government point of contact within fourteen (14) days of receiving the respective batch shipment. Each batch shipment will contain at least eight (8) but no more than thirty-two (32) samples. 3. Tasks: The complete amount of samples will be submitted within twelve (12) months from the date of contract award. Groups and sample sizes are as follows: Fentanyl and Norfentanyl, Rabbit Serum/Plasma; n = 132 Fentanyl and Norfentanyl, Porcine Serum/Plasma; n = 132 Buprenorphine and Norbuprenorphine - Free (Unconjugated) Serum/Plasma; n = 48 4. Type of Contract: Firm-Fixed-Price 5. Payment will be made utilizing Wide Area Work Flow (WAWF). 6. A Contracting Officer's Representative will be assigned upon award of contract. 7. Period of Performance: Twelve (12) months from date of award 8. Deliverables: A written report of the results of each batch submitted shall be delivered to the Government point of contact no later than fourteen (14) days after the contractor's receipt of the respective batch of samples. Each report will contain the analysis results of each Fentanyl and Norfentanyl serum sample and/or the Buprenorphine and Norbuprenorphine serum sample submitted with that batch, reported in ng/mL. SUBMISSION OF QUOTES/PROPOSALS General Information Introduction and Purpose - This section specifies the format and content that offerors shall use in responding to this Request for Quote (RFQ). The Government intends to evaluate proposals and award without discussions with contractors, however, the Government reserves the right to conduct discussions if the Contracting Officer (KO) determines that it is deemed necessary. The Government may reject any or all proposals if such action is in the Government's best interest; accept other than the lowest proposal; and waive informalities and minor irregularities in proposals received. QUOTES MUST BE ACCOMPANIED BY A BRIEF (ONE TO TWO PAGE) NARRATIVE ADDRESSING THE TECHNICAL CAPABILITY AND PAST PERFORMANCE EVALUATION FACTORS DESCRIBED IN PROVISION 52.212-2 quote mark EVALUATION - COMMERCIAL ITEMS (JAN 1999) quote mark AND FOUND BELOW*. SUBMISSION OF QUOTES: Quotes and all required supporting documentation must be received by the contract specialist no later than 5:00 PM CDT, 18 September 2013 via email to terry.g.bice.civ@mail.mil. Contract Specialist The Contract Specialist (CS) is the point of contact for this acquisition. Any questions or concerns regarding this acquisition shall be submitted electronically via e-mail to Mr. Terry Bice at terry.g.bice.civ@mail.mil. Evaluation Factors (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: i.Technical Capability ii.Past Performance iii.Price Technical and past performance, when combined, are significantly more important than price. Technical is significantly more important than Past Performance. Past Performance is more important than price. *Technical Capability 1. In addition to the quote, offerors shall clearly demonstrate their capabilty to meet all technical requirements for analyzing the therapeutic drugs and metabolites listed in the performance work statement (PWS) at the stated sensitivity level. 2. The offeror must be capable of delivering the required services within the period of performance stated in the PWS. 3. The offeror must be capable of meeting the reporting requirements stated in the PWS. *Past Performance The offeror's proposal shall demonstrate in narrative, performance of services of same or similar nature to that described in the PWS over the past three (3) years. A contract of a similar nature is a contract of comparable risk- the functions, responsibilities, and control exercised by the offeror are essentially the same as that required under the PWS. The offeror's performance will be evaluated to determine if the services were performed in a timely, professional manner, and in accordance with all contract requirements. In addition to the above, the following information should be provided: -Project or contract title; -Contract number, contracting agency, type of contract, and total current dollar value; -Date of contract and period of performance; -Firm or Government agency for which work was performed, including address and telephone number; -Point of contact (Project Manager or Contracting Officer), name, title, address, email and phone number; -Brief description of how the cited work is the same as or similar to the proposed effort. Note: Government source selection evaluators will verify past performance information and may solicit additional recent information from other sources. Past performance information may be obtained from any other sources available to the Government, to include, but not limited to, the Past Performance Information Retrieval System (PPIRS), Federal Awardee Performance and Integrity Information System (FAPIIS), Electronic Subcontract Reporting System (eSRS), System for Award Management (SAM), or other databases; interviews with Program Managers, Contracting Officers, and the Defense Contract Management Agency (DCMA). In the case of an offeror without a record of relevant past performance or for whom information on past performance is not available or so sparse that no meaningful past performance rating can be reasonable assigned, the offeror may not be evaluated favorably or unfavorably on at performance. Therefore, the offeror shall be determined to have an unknown past performance. In the context of acceptability/unacceptability quote mark unknown quote mark shall be considered quote mark acceptable quote mark. Price Factor The contract will be a firm fixed-price contract. The Government will evaluate price reasonableness for the fixed priced effort. The Government will examine price proposals for artificially high/low prices. Offers found to be unreasonably high, unrealistically low (an indication of quote mark buy -in quote mark ), or unbalanced, may be considered unacceptable and may be rejected on the basis that the unrealistic price represents an inherent lack of technical competence or indicative of failure to comprehend the proposed contractual requirement. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (End of Summary of Changes)
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-13-T-0369/listing.html)
- Place of Performance
- Address: US Army Medical Research Acquisition Activity ATTN: MCMR-AAA, 820 Chandler Street Frederick MD
- Zip Code: 21702-5014
- Zip Code: 21702-5014
- Record
- SN03187165-W 20130915/130913235236-ad7e05af3ff4de84bf766a0b723d71a8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |